Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1967 Jun 10;96(23):1513–1520.

The Biopharmaceutical Properties of Solid Dosage Forms

I. An Evaluation of 23 Brands of Phenylbutazone Tablets

R O Searl, M Pernarowski
PMCID: PMC1923035  PMID: 6026336

Abstract

The potency, disintegration and dissolution characteristics of 23 brands of phenylbutazone tablets were determined. Five (21.7%) of the 23 brands failed to comply with the minimum requirements of the compendia or the regulations appended to the Food and Drugs Act. The in vitro characteristics of four brands were substantially different from those that disintegrated and released the drug satisfactorily. The in vivo characteristics of three of the four brands were compared with those observed for a pharmaceutically acceptable product. The latter product released the drug to the blood quickly, but the former products released the drug only after the tablets had been in the body for six to eight hours and, in the case of one product, released quantities much below those that would be acceptable to the physician. These results show that different products containing the same drug are not necessarily equivalent. This is contrary to the generic equivalency hypothesis which assumes that all products comply with specifications and, therefore, must be clinically effective.

Full text

PDF
1513

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BURNS J. J., ROSE R. K., CHENKIN T., GOLDMAN A., SCHULERT A., BRODIE B. B. The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther. 1953 Nov;109(3):346–357. [PubMed] [Google Scholar]
  2. CAMPAGNA F. A., CURETON G., MIRIGIAN R. A., NELSON E. Inactive prednisone tablets U.S.P. XVI. J Pharm Sci. 1963 Jun;52:605–606. doi: 10.1002/jps.2600520626. [DOI] [PubMed] [Google Scholar]
  3. DELGADO J. N., COSGROVE F. P. FALLACIES OF GENERIC EQUIVALENCE THESIS. II. PHYSICO-CHEMICAL AND PHARMACEUTIC FACTORS AFFECTING GASTROINTESTINAL ABSORPTION. Tex Med. 1963 Nov;59:1106–1112. [PubMed] [Google Scholar]
  4. GWILT J. R., ROBERTSON A., GOLDMAN L., BLANCHARD A. W. The absorption characteristics of paracetamol tablets in man. J Pharm Pharmacol. 1963 Jul;15:445–453. doi: 10.1111/j.2042-7158.1963.tb12812.x. [DOI] [PubMed] [Google Scholar]
  5. LEVY G., HAYES B. A. Physicochemical basis of the buffered acetylsalicylic acid controversy. N Engl J Med. 1960 May 26;262:1053–1058. doi: 10.1056/NEJM196005262622102. [DOI] [PubMed] [Google Scholar]
  6. LEVY G., NELSON E. Pharmaceutical formulation and therapeutic efficacy. JAMA. 1961 Sep 9;177:689–691. doi: 10.1001/jama.1961.03040360025004. [DOI] [PubMed] [Google Scholar]
  7. SCHROETER L. C., TINGSTAD J. E., KNOECHELEL, WAGNER J. G. Specificity of the relationship between rate of dissolution and disintegration time of compressed tablets. J Pharm Sci. 1962 Sep;51:865–874. doi: 10.1002/jps.2600510912. [DOI] [PubMed] [Google Scholar]
  8. STEPHENS C. A. L., Jr, YEOMAN E. E., HOLBROOK W. P., HILL D. F., GOODIN W. L. Benefits and toxicity of phenylbutazone (butazolidin) in rheumatoid arthritis. J Am Med Assoc. 1952 Nov 15;150(11):1084–1086. doi: 10.1001/jama.1952.03680110024007. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES